Lactate dehydrogenase isoenzyme 3 and hemolysis in sickle cell anemia: A possible correlation?

Blood

Volumn 125, Issue 24, 2015, Pages 3821-3822

  Mecabo, Grazielle ^a   Yamamoto, Mihoko ^a   Biassi, Thais Priscila ^a   Figueiredo, Maria Stella ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; LACTATE DEHYDROGENASE 1; LACTATE DEHYDROGENASE 2; LACTATE DEHYDROGENASE 4; LACTATE DEHYDROGENASE 5; LACTATE DEHYDROGENASE ISOENZYME; LACTATE DEHYDROGENASE ISOENZYME 3; UNCLASSIFIED DRUG; ANTISICKLING AGENT; BIOLOGICAL MARKER; ISOENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 3;

ADULT; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHORETIC MOBILITY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; HEART MUSCLE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HUMAN CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TISSUE INJURY; ANEMIA, SICKLE CELL; BLOOD; DRUG EFFECTS; ENZYMOLOGY; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BIOLOGICAL MARKERS; CHILD, PRESCHOOL; FEMALE; HEMOLYSIS; HUMANS; HYDROXYUREA; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; YOUNG ADULT;

EID: 84930966039     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-641522     Document Type: Letter

References (10)

1. Ballas SK. Lactate dehydrogenase and hemolysis in sickle cell disease. Blood. 2013;121(1):243-244.
2. Neely CL, Wajima T, Kraus AP, Diggs LW, Barreras L. Lactic acid dehydrogenase activity and plasma hemoglobin elevations in sickle cell disease. Am J Clin Pathol. 1969;52(2):167-169.
3. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-2285.
4. Kato GJ, Nouraie SM, Gladwin MT. Lactate dehydrogenase and hemolysis in sickle cell disease. Blood. 2013;122(6):1091-1092.
5. Johnson-Davis KL. Enzymes. In: Bishop ML, Fody EP, Schoeff LE, eds. Clinical Chemistry: Principles, Techniques, and Correlations. Philadelphia, PA: Wolters Kluwer. 2013:262-291.
6. van Beers EJ, Schaap MC, Berckmans RJ, et al; CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009;94(11):1513-1519.
7. Pattanapanyasat K, Noulsri E, Fucharoen S, et al. Flow cytometric quantitation of red blood cell vesicles in thalassemia. Cytometry B Clin Cytom. 2004;57(1):23-31.
8. Kupesiz A, Celmeli G, Dogan S, Antmen B, Aslan M. The effect of hemolysis on plasma oxidation and nitration in patients with sickle cell disease. Free Radic Res. 2012;46(7):883-890.
9. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354-2363.
10. Steinberg MH, McCarthy WF, Castro O, et al Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403-408.